LivaNova (NASDAQ:LIVN) Downgraded by StockNews.com to “Buy”

StockNews.com downgraded shares of LivaNova (NASDAQ:LIVN) from a strong-buy rating to a buy rating in a research note released on Thursday morning.

Several other analysts have also commented on the stock. Mizuho reduced their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. The Goldman Sachs Group initiated coverage on LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 price target on the stock. Robert W. Baird raised their price objective on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 target price on shares of LivaNova in a research report on Monday, November 25th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $69.17.

LivaNova Price Performance

Shares of LIVN stock opened at $48.82 on Thursday. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a market capitalization of $2.65 billion, a PE ratio of 116.24 and a beta of 1.01. The firm’s 50-day moving average is $49.26 and its two-hundred day moving average is $50.02. LivaNova has a 12 month low of $43.15 and a 12 month high of $64.47.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the sale, the director now directly owns 7,522 shares in the company, valued at $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.27% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. KBC Group NV lifted its holdings in LivaNova by 130.5% during the 4th quarter. KBC Group NV now owns 99,928 shares of the company’s stock worth $4,628,000 after buying an additional 56,580 shares in the last quarter. Harbor Capital Advisors Inc. purchased a new stake in shares of LivaNova during the fourth quarter worth $1,954,000. Diversified Trust Co raised its stake in shares of LivaNova by 9.5% in the fourth quarter. Diversified Trust Co now owns 16,432 shares of the company’s stock valued at $761,000 after acquiring an additional 1,425 shares in the last quarter. Nordea Investment Management AB boosted its holdings in LivaNova by 22.2% in the fourth quarter. Nordea Investment Management AB now owns 68,711 shares of the company’s stock valued at $3,188,000 after purchasing an additional 12,470 shares during the period. Finally, Central Pacific Bank Trust Division grew its stake in LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after purchasing an additional 720 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.